Acute profound thrombocytopenia after using abciximab for no-reflow during primary percutaneous coronary intervention for ST-Segment elevation myocardial infarction

Korean Circulation Journal

Volumn 43, Issue 8, 2013, Pages 557-560

  Park, Soonyoung ^a   Lee, Jooyoung ^a   Lee, Sang Yeub ^a   Bae, Jang Whan ^a   Hwang, Kyung Kuk ^a   Kim, Dong Woon ^a   Cho, Myeong Chan ^a   Kim, Sang Min ^a  

^a Chungbuk National University Hospital   (South Korea)

Author keywords

Abciximab; No reflow phenomenon; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BLOOD CLOT LYSIS; CASE REPORT; COLLATERAL CIRCULATION; COMPLETE HEART BLOCK; HUMAN; MALE; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS PREVENTION;

EID: 84885450875     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2013.43.8.557     Document Type: Article

References (11)

1. Makoni SN. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature. Heart 2001;86:E18.
2. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-80.
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
4. Lincoff AM, Mark DB, Tcheng JE, et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 2000;102: 2923-9.
5. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
6. Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109:2203-6. (Pubitemid 38625397)
7. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-55. (Pubitemid 36645375)
8. Claeys LG, Berg W. Major bleeding and severe thrombocytopenia after combined heparin and abciximab-c7E3 Fab therapy. Eur J Vasc Endovasc Surg 2003;25:85-7. (Pubitemid 36527607)
9. Klein LW, Kern MJ, Berger P, et al. Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2003;60:194-201. (Pubitemid 37203996)
10. Butler MJ, Chan W, Taylor AJ, Dart AM, Duffy SJ. Management of the no-reflow phenomenon. Pharmacol Ther 2011;132:72-85.
11. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-82.